Energy in a cell and energy on a staircase
“Energy” can mean a chemical reaction or enough get-up-and-go to carry laundry upstairs. Same word, rather different questions. I look for which one a paper actually tested.
NAD+ helps cells turn fuel into usable energy. Its full name is nicotinamide adenine dinucleotide. It’s a coenzyme, a small helper molecule, rather than a peptide. You don’t need to memorise the name to see why it belongs in this conversation.
The useful question is what changed for the person. A result inside a cell leaves that part of the story open.
MOTS-c connects cell stress with fuel handling
MOTS-c is a short peptide whose recipe sits in mitochondria, the cell’s energy-making structures. In the first cell and mouse study, treated mice on a high-fat diet gained less weight and handled sugar better than untreated mice.
What about people? FDA’s review found no published studies giving MOTS-c to humans. A registered trial in adults with prediabetes, a blood-sugar condition, and extra weight sets out a test, but supplies no results.
A trial plan is worth knowing about. It’s also worth leaving the answer blank until there is one.
NAD+ has a precursor problem in the wording
NMN, nicotinamide mononucleotide, and NR, nicotinamide riboside, are precursors: materials the body uses to make NAD+. Giving one of those isn’t the same as giving NAD+ itself.
One NMN trial in women past menopause who had prediabetes found that muscle responded better to insulin, the hormone that helps manage blood sugar. Neither body composition nor a measure of blood sugar over time changed in that trial. That doesn’t answer whether someone feels less tired.
A review of human precursor trials found changes in NAD-related measurements more consistently than gains in how people functioned. A better-looking measurement can still leave the stairs feeling like stairs.
The safety question stays open
MOTS-c is not FDA-approved. Its human safety is unknown, and basic animal safety tests are missing. For injected forms, FDA flags impurities, clumping and unwanted immune reactions. These are concerns, not measured rates of harm in people.
The precursor studies had limited follow-up. They don’t establish long-term safety or the safety of NAD+ infusions. Persistent tiredness is a question for a licensed U.S. clinician who can assess the symptom itself.